|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||25.35 - 26.92|
|52-week range||7.37 - 29.90|
|PE ratio (TTM)||N/A|
|Earnings date||7 Mar 2018 - 12 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||31.80|
CANTON, Mass., March 19, 2018-- Collegium Pharmaceutical, Inc. today announced the appointment of Shirley Kuhlmann to the newly created position of Executive Vice President and General Counsel and Secretary, ...
CANTON, Mass., March 16, 2018-- Collegium Pharmaceutical, Inc. today announced that management will present at the following investor conferences in March:. The Oppenheimer & Company 28 th Annual Healthcare ...
Collegium touched a buy zone Thursday after sales of painkiller Xtampza easily beat Street expectations in the fourth quarter.
On a per-share basis, the Canton, Massachusetts-based company said it had a loss of 54 cents. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Xtampza ER prescriptions grew by 37% in the fourth quarter FDA Approval of sNDA, including Comparative OxyContin Data in label Expanded product portfolio by licensing rights to commercialize Nucynta franchise ...
CANTON, Mass., Feb. 26, 2018-- Collegium Pharmaceutical, Inc. announced today that the Company will host a conference call and live audio webcast on Wednesday, March 7, 2018 at 4:30 p.m. Eastern Time. ...
NEW YORK, Feb. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Electronic ...
With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.
Establishes Collegium as a leader in responsible pain management Broadens portfolio of meaningfully differentiated products Immediately accretive, accelerates time to profitability Leverages Collegium’ ...
Collegium rocketed to a 22-month high Tuesday after striking a deal with Depomed to commercialize its painkiller Nucynta.
The FDA is working on ways to encourage the development of abuse-deterrent opioid pain relievers, and that's potentially bad news for this tiny biotech.